Cytokine imbalance in the pathophysiology of major depressive disorder

Yong Ku Kim, Kyeong Sae Na, Kyung-Ho Shin, Han Yong Jung, So Hyun Choi, Jung Bum Kim

Research output: Contribution to journalArticle

199 Citations (Scopus)

Abstract

Objective: A substantial body of evidence indicates that dysregulation of the immune system is associated with Major Depressive Disorder (MDD). Because most cytokines have pleiotropic effects, we measured various subsets of cytokines to examine the association between immune response and MDD. Methods: Forty-eight hospitalized MDD patients and 63 normal controls were recruited. We measured in vitro monocytic (IL-6 and tumor necrosis factor (TNF)-alpha), Th1 (interferon (IFN)-gamma and interleukin (IL)-2), Th2 (IL-4), and Treg (transforming growth factor (TGF)-beta1) cytokine production as well as IL-2/IL-4 and IFN-gamma/IL-4 ratios for both groups. Depressive symptoms were assessed by Hamilton Depression Rating Scale. Patients were evaluated before and after 6 weeks of antidepressant treatment. Results: At admission, IL-6, TNF-alpha, TGF-beta1 production, and IFN-gamma/IL-4 ratio were significantly higher, whereas IFN-gamma, IL-2, and IL-4 were significantly lower in MDD patients. After treatment, IL-6 and TGF-beta1 production were significantly lower than before treatment. Conclusion: We suggest that activation of monocytic proinflammatory cytokines, and inhibition of both Th1 and Th2 cytokines may be associated with immunological dysregulation in MDD. TGF-beta1 may be associated with the regulation of monocytic cytokines as well as Th1 and Th2 cytokines in MDD.

Original languageEnglish
Pages (from-to)1044-1053
Number of pages10
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume31
Issue number5
DOIs
Publication statusPublished - 2007 Jun 30

Fingerprint

Major Depressive Disorder
Transforming Growth Factor beta1
Cytokines
Interleukin-4
Interferon-gamma
Interleukin-2
Interleukin-6
Tumor Necrosis Factor-alpha
Depression
Interferon-alpha
Antidepressive Agents
Immune System
Therapeutics

Keywords

  • Antidepressants
  • Cytokines
  • Interferons
  • Interleukins
  • Psychoimmunology
  • Transforming growth factors

ASJC Scopus subject areas

  • Pharmacology
  • Biological Psychiatry

Cite this

Cytokine imbalance in the pathophysiology of major depressive disorder. / Kim, Yong Ku; Na, Kyeong Sae; Shin, Kyung-Ho; Jung, Han Yong; Choi, So Hyun; Kim, Jung Bum.

In: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 31, No. 5, 30.06.2007, p. 1044-1053.

Research output: Contribution to journalArticle

Kim, Yong Ku ; Na, Kyeong Sae ; Shin, Kyung-Ho ; Jung, Han Yong ; Choi, So Hyun ; Kim, Jung Bum. / Cytokine imbalance in the pathophysiology of major depressive disorder. In: Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2007 ; Vol. 31, No. 5. pp. 1044-1053.
@article{65a36a261d7b4f01811a260bf05d5186,
title = "Cytokine imbalance in the pathophysiology of major depressive disorder",
abstract = "Objective: A substantial body of evidence indicates that dysregulation of the immune system is associated with Major Depressive Disorder (MDD). Because most cytokines have pleiotropic effects, we measured various subsets of cytokines to examine the association between immune response and MDD. Methods: Forty-eight hospitalized MDD patients and 63 normal controls were recruited. We measured in vitro monocytic (IL-6 and tumor necrosis factor (TNF)-alpha), Th1 (interferon (IFN)-gamma and interleukin (IL)-2), Th2 (IL-4), and Treg (transforming growth factor (TGF)-beta1) cytokine production as well as IL-2/IL-4 and IFN-gamma/IL-4 ratios for both groups. Depressive symptoms were assessed by Hamilton Depression Rating Scale. Patients were evaluated before and after 6 weeks of antidepressant treatment. Results: At admission, IL-6, TNF-alpha, TGF-beta1 production, and IFN-gamma/IL-4 ratio were significantly higher, whereas IFN-gamma, IL-2, and IL-4 were significantly lower in MDD patients. After treatment, IL-6 and TGF-beta1 production were significantly lower than before treatment. Conclusion: We suggest that activation of monocytic proinflammatory cytokines, and inhibition of both Th1 and Th2 cytokines may be associated with immunological dysregulation in MDD. TGF-beta1 may be associated with the regulation of monocytic cytokines as well as Th1 and Th2 cytokines in MDD.",
keywords = "Antidepressants, Cytokines, Interferons, Interleukins, Psychoimmunology, Transforming growth factors",
author = "Kim, {Yong Ku} and Na, {Kyeong Sae} and Kyung-Ho Shin and Jung, {Han Yong} and Choi, {So Hyun} and Kim, {Jung Bum}",
year = "2007",
month = "6",
day = "30",
doi = "10.1016/j.pnpbp.2007.03.004",
language = "English",
volume = "31",
pages = "1044--1053",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Cytokine imbalance in the pathophysiology of major depressive disorder

AU - Kim, Yong Ku

AU - Na, Kyeong Sae

AU - Shin, Kyung-Ho

AU - Jung, Han Yong

AU - Choi, So Hyun

AU - Kim, Jung Bum

PY - 2007/6/30

Y1 - 2007/6/30

N2 - Objective: A substantial body of evidence indicates that dysregulation of the immune system is associated with Major Depressive Disorder (MDD). Because most cytokines have pleiotropic effects, we measured various subsets of cytokines to examine the association between immune response and MDD. Methods: Forty-eight hospitalized MDD patients and 63 normal controls were recruited. We measured in vitro monocytic (IL-6 and tumor necrosis factor (TNF)-alpha), Th1 (interferon (IFN)-gamma and interleukin (IL)-2), Th2 (IL-4), and Treg (transforming growth factor (TGF)-beta1) cytokine production as well as IL-2/IL-4 and IFN-gamma/IL-4 ratios for both groups. Depressive symptoms were assessed by Hamilton Depression Rating Scale. Patients were evaluated before and after 6 weeks of antidepressant treatment. Results: At admission, IL-6, TNF-alpha, TGF-beta1 production, and IFN-gamma/IL-4 ratio were significantly higher, whereas IFN-gamma, IL-2, and IL-4 were significantly lower in MDD patients. After treatment, IL-6 and TGF-beta1 production were significantly lower than before treatment. Conclusion: We suggest that activation of monocytic proinflammatory cytokines, and inhibition of both Th1 and Th2 cytokines may be associated with immunological dysregulation in MDD. TGF-beta1 may be associated with the regulation of monocytic cytokines as well as Th1 and Th2 cytokines in MDD.

AB - Objective: A substantial body of evidence indicates that dysregulation of the immune system is associated with Major Depressive Disorder (MDD). Because most cytokines have pleiotropic effects, we measured various subsets of cytokines to examine the association between immune response and MDD. Methods: Forty-eight hospitalized MDD patients and 63 normal controls were recruited. We measured in vitro monocytic (IL-6 and tumor necrosis factor (TNF)-alpha), Th1 (interferon (IFN)-gamma and interleukin (IL)-2), Th2 (IL-4), and Treg (transforming growth factor (TGF)-beta1) cytokine production as well as IL-2/IL-4 and IFN-gamma/IL-4 ratios for both groups. Depressive symptoms were assessed by Hamilton Depression Rating Scale. Patients were evaluated before and after 6 weeks of antidepressant treatment. Results: At admission, IL-6, TNF-alpha, TGF-beta1 production, and IFN-gamma/IL-4 ratio were significantly higher, whereas IFN-gamma, IL-2, and IL-4 were significantly lower in MDD patients. After treatment, IL-6 and TGF-beta1 production were significantly lower than before treatment. Conclusion: We suggest that activation of monocytic proinflammatory cytokines, and inhibition of both Th1 and Th2 cytokines may be associated with immunological dysregulation in MDD. TGF-beta1 may be associated with the regulation of monocytic cytokines as well as Th1 and Th2 cytokines in MDD.

KW - Antidepressants

KW - Cytokines

KW - Interferons

KW - Interleukins

KW - Psychoimmunology

KW - Transforming growth factors

UR - http://www.scopus.com/inward/record.url?scp=34249325459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249325459&partnerID=8YFLogxK

U2 - 10.1016/j.pnpbp.2007.03.004

DO - 10.1016/j.pnpbp.2007.03.004

M3 - Article

VL - 31

SP - 1044

EP - 1053

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

IS - 5

ER -